Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 1998

View Archived Issues

Predictors of vascular access site complications during angioplasty with eptifibatide

Zopiclone improves sleep in rheumatoid arthritis patients

Cardiotoxicity of dexverapamil makes it unsuitable for reversing resistance in breast cancer

New estrogenic/antioxidant agents developed by AHP

Japan Energy prepares HIV protease-inhibitory dipeptides

NMDA subtype-selective blockers prepared and evaluated at Roche

Investigation at Sumitomo leads to new psychotropic agents

PDE inhibitors from Kyorin useful as bronchodilators

Alizyme granted exclusive worldwide license to BTG drug delivery technology

Avax to begin pivotal trial with M-Vax in melanoma patients

Schizophrenia collaboration between Neurogen and Schering-Plough ends successfully

Label expansion for CEPRATE SC approved

Clinical trials to begin shortly with KT-7515/CEP-1347

Antifungal therapeutics, diagnostics collaboration initiated by Phytera and Lilly

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...